{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T18:47:38Z","timestamp":1782413258707,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oxaliplatin (OXA), a key cytotoxic agent used in the treatment of gastrointestinal cancers, is frequently discontinued due to hypersensitivity reactions (HSRs). We developed a protocol to mitigate HSRs and assessed its clinical efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed HSRs in patients with metastatic colorectal cancer (mCRC) who were treated with OXA-containing regimens between 2005 and 2019. We evaluated the clinical utility of our HSR prevention protocol in patients who experienced grade 1\u20133 HSRs following OXA-based chemotherapy. The protocol involved increasing dexamethasone to 16.5\u00a0mg\/body and extending the OXA infusion time from 2 to 4\u00a0h.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 205 patients, 105 (51.2%) experienced grade 1, 95 (46.3%) grade 2, and 5 (2.4%) grade 3 HSRs. Most patients (87.8%) received either the FOLFOX4 or modified FOLFOX6 regimen. Patients underwent a median of 11 OXA cycles before their initial HSR. OXA was successfully reintroduced in 108 patients (52.7%) using the HSR prevention protocol. The median OXA-free interval was 23\u00a0days and the median progression-free survival after reintroduction was 6.4\u00a0months (95% confidence interval [CI]: 4.6\u20138.2). Reasons for discontinuation included a second HSR in 97 patients (47.3%), disease progression in 74 (36.1%), and chemotherapy-induced peripheral neuropathy (CIPN) in 15 (7.3%). Forty-six patients (22.4%) experienced an HSR during the initial prevention protocol. Only six patients (2.9%) experienced grade 3 HSRs and no grade 4 or 5 events were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High-dose dexamethasone and prolonged infusion time may enable OXA reintroduction, providing an alternative to permanent discontinuation in mCRC patients with prior HSRs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registry number<\/jats:title>\n                    <jats:p>2024-GB-073 (retrospectively registered).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-03037-8","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:07:10Z","timestamp":1779880030000},"page":"1245-1257","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High-dose dexamethasone and prolonged infusion time prevent oxaliplatin-related hypersensitivity reactions in patients with metastatic colorectal cancer"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9877-9336","authenticated-orcid":false,"given":"Koichiro","family":"Yoshino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4742-0446","authenticated-orcid":false,"given":"Hiroki","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7618-5775","authenticated-orcid":false,"given":"Akira","family":"Ooki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2225-7346","authenticated-orcid":false,"given":"Shohei","family":"Udagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1380-4325","authenticated-orcid":false,"given":"Mikako","family":"Tamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9460-4486","authenticated-orcid":false,"given":"Shota","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-3859","authenticated-orcid":false,"given":"Takeru","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1004-8425","authenticated-orcid":false,"given":"Mariko","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2015-8185","authenticated-orcid":false,"given":"Keisho","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6887-5709","authenticated-orcid":false,"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7448-5894","authenticated-orcid":false,"given":"Eiji","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"3","key":"3037_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"3037_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7(8):573\u2013584","journal-title":"Nat Rev Cancer"},{"issue":"Suppl 4 (Suppl","key":"3037_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/bjc.1998.428","volume":"77","author":"JL Misset","year":"1998","unstructured":"Misset JL (1998) Oxaliplatin in practice. Br J Cancer 77(Suppl 4 (Suppl 4)):4\u20137","journal-title":"Br J Cancer"},{"issue":"1","key":"3037_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S et al (2023) Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34(1):10\u201332","journal-title":"Ann Oncol"},{"issue":"3","key":"3037_CR5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris VK, Kennedy EB, Baxter NN et al (2023) Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol 41(3):678\u2013700","journal-title":"J Clin Oncol"},{"issue":"8","key":"3037_CR6","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386\u20131422","journal-title":"Ann Oncol"},{"issue":"3","key":"3037_CR7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, Venook AP, Al-Hawary MM et al (2021) Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19(3):329\u201359","journal-title":"J Natl Compr Canc Netw"},{"key":"3037_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102180","volume":"96","author":"S De Dosso","year":"2021","unstructured":"De Dosso S, Siebenhuner AR, Winder T et al (2021) Treatment landscape of metastatic pancreatic cancer. Cancer Treat Rev 96:102180","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"3037_CR9","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s10147-015-0938-9","volume":"21","author":"C Hamada","year":"2016","unstructured":"Hamada C, Yamada Y, Azuma M et al (2016) Meta-analysis supporting noninferiority of oxaliplatin plus S-1 to cisplatin plus S-1 in first-line treatment of advanced gastric cancer (G-SOX study): indirect comparison with S-1 alone. Int J Clin Oncol 21(4):668\u2013675","journal-title":"Int J Clin Oncol"},{"issue":"10294","key":"3037_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294):27\u201340","journal-title":"Lancet"},{"issue":"10","key":"3037_CR11","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ et al (2020) Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol 6(10):1571\u20131580","journal-title":"JAMA Oncol"},{"issue":"9742","key":"3037_CR12","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687\u2013697","journal-title":"Lancet"},{"key":"3037_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061502","author":"P Di Nardo","year":"2022","unstructured":"Di Nardo P, Garattini SK, Torrisi E et al (2022) Systemic treatments for advanced small bowel adenocarcinoma: a systematic review. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14061502","journal-title":"Cancers (Basel)"},{"issue":"3","key":"3037_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","volume":"20","author":"Y Kitagawa","year":"2023","unstructured":"Kitagawa Y, Ishihara R, Ishikawa H et al (2023) Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: Part 1. Esophagus 20(3):343\u2013372","journal-title":"Esophagus"},{"issue":"4","key":"3037_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/ajco.12995","volume":"14","author":"H Hirano","year":"2018","unstructured":"Hirano H, Boku N (2018) The current status of multimodality treatment for unresectable locally advanced esophageal squamous cell carcinoma. Asia Pac J Clin Oncol 14(4):291\u2013299","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"3037_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","volume":"82","author":"AA Argyriou","year":"2012","unstructured":"Argyriou AA, Bruna J, Marmiroli P et al (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82(1):51\u201377","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"3037_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/sj.bjc.6601155","volume":"89","author":"G Brandi","year":"2003","unstructured":"Brandi G, Pantaleo MA, Galli C et al (2003) Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 89(3):477\u2013481","journal-title":"Br J Cancer"},{"issue":"2","key":"3037_CR18","first-page":"92","volume":"2","author":"DMR Hunter","year":"1945","unstructured":"Hunter DMR, Perry KMA (1945) Asthma caused by the complex salts of platinum. Br J Ind Med 2(2):92\u201398","journal-title":"Br J Ind Med"},{"issue":"2","key":"3037_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2222.1976.tb01897.x","volume":"6","author":"MJ Cleare","year":"1976","unstructured":"Cleare MJ, Hughes EG, Jacoby B et al (1976) Immediate (type I) allergic responses to platinum compounds. Clin Allergy 6(2):183\u2013195","journal-title":"Clin Allergy"},{"issue":"4","key":"3037_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/BF00689458","volume":"35","author":"AA Shlebak","year":"1995","unstructured":"Shlebak AA, Clark PI, Green JA (1995) Hypersensitivity and cross-reactivity to cisplatin and analogues. Cancer Chemother Pharmacol 35(4):349\u2013351","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"3037_CR21","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","volume":"17","author":"M Markman","year":"1999","unstructured":"Markman M, Kennedy A, Webster K et al (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17(4):1141","journal-title":"J Clin Oncol"},{"issue":"8","key":"3037_CR22","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1002\/1097-0142(19940415)73:8<2218::AID-CNCR2820730830>3.0.CO;2-1","volume":"73","author":"B Weidmann","year":"1994","unstructured":"Weidmann B, M\u00fclleneisen N, Bojko P et al (1994) Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management. Cancer 73(8):2218\u20132222","journal-title":"Cancer"},{"key":"3037_CR23","doi-asserted-by":"crossref","unstructured":"Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW (2010) Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs. 2010;2010.","DOI":"10.1155\/2010\/207084"},{"issue":"Suppl 10","key":"3037_CR24","doi-asserted-by":"publisher","first-page":"x313","DOI":"10.1093\/annonc\/mds314","volume":"23","author":"M Joerger","year":"2012","unstructured":"Joerger M (2012) Prevention and handling of acute allergic and infusion reactions in oncology. Ann Oncol 23(Suppl 10):x313\u2013x319","journal-title":"Ann Oncol"},{"issue":"1","key":"3037_CR25","first-page":"68","volume":"23","author":"BB Rogers","year":"2019","unstructured":"Rogers BB, Cuddahy T, Briscella C et al (2019) Oxaliplatin: detection and management of hypersensitivity reactions. Clin J Oncol Nurs 23(1):68\u201375","journal-title":"Clin J Oncol Nurs"},{"issue":"9","key":"3037_CR26","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s00262-012-1273-x","volume":"61","author":"M Castells","year":"2012","unstructured":"Castells M, Sancho-Serra MdC, Simarro M (2012) Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. Cancer Immunol Immunother 61(9):1575\u20131584","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"3037_CR27","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s10147-010-0170-6","volume":"16","author":"Y Kidera","year":"2011","unstructured":"Kidera Y, Satoh T, Ueda S et al (2011) High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol 16(3):244\u2013249","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"3037_CR28","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.clinthera.2015.03.012","volume":"37","author":"T Okayama","year":"2015","unstructured":"Okayama T, Ishikawa T, Sugatani K et al (2015) Hypersensitivity reactions to oxaliplatin: identifying the risk factors and judging the efficacy of a desensitization protocol. Clin Ther 37(6):1259\u20131269","journal-title":"Clin Ther"},{"issue":"4","key":"3037_CR29","first-page":"2461","volume":"14","author":"Q Song","year":"2022","unstructured":"Song Q, Cai Y, Guo K et al (2022) Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer. Am J Transl Res 14(4):2461\u20132468","journal-title":"Am J Transl Res"},{"key":"3037_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/2050-6511-15-1","volume":"15","author":"M Parel","year":"2014","unstructured":"Parel M, Ranchon F, Nosbaum A et al (2014) Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol 15:1","journal-title":"BMC Pharmacol Toxicol"},{"issue":"12","key":"3037_CR31","first-page":"5521","volume":"32","author":"T Yanai","year":"2012","unstructured":"Yanai T, Iwasa S, Hashimoto H et al (2012) Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer. Anticancer Res 32(12):5521\u20135526","journal-title":"Anticancer Res"},{"issue":"2","key":"3037_CR32","first-page":"106","volume":"8","author":"EI Syrigou","year":"2009","unstructured":"Syrigou EI, Karapanagiotou EM, Alamara CV (2009) Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clin Colorectal Cancer 8(2):106\u2013109","journal-title":"Clin Colorectal Cancer"},{"issue":"9","key":"3037_CR33","first-page":"3179","volume":"27","author":"D Botsen","year":"2019","unstructured":"Botsen D, Lepoix E, Mazza C et al (2019) Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France. Support Care Cancer 27(9):3179\u20133182","journal-title":"Support Care Cancer"},{"issue":"3","key":"3037_CR34","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12094-012-0909-9","volume":"15","author":"S Cortijo-Cascajares","year":"2013","unstructured":"Cortijo-Cascajares S, Nacle-L\u00f3pez I, Garc\u00eda-Escobar I et al (2013) Effectiveness of oxaliplatin desensitization protocols. Clin Transl Oncol 15(3):219\u2013225","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"3037_CR35","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1001\/jamaoncol.2022.7136","volume":"9","author":"E Rassy","year":"2023","unstructured":"Rassy E, Le Roy F, Smolenschi C et al (2023) Rechallenge after oxaliplatin-induced hypersensitivity reactions. JAMA Oncol 9(3):434\u2013435","journal-title":"JAMA Oncol"},{"issue":"3","key":"3037_CR36","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"3037_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bcp.12297","volume":"78","author":"SF Stone","year":"2014","unstructured":"Stone SF, Phillips EJ, Wiese MD (2014) Immediate-type hypersensitivity drug reactions. Br J Clin Pharmacol 78(1):1\u201313","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3037_CR38","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ygyno.2009.10.070","volume":"116","author":"R O\u2019Cearbhaill","year":"2010","unstructured":"O\u2019Cearbhaill R, Zhou Q, Iasonos A et al (2010) The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecol Oncol 116(3):326\u2013331","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3037_CR39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","volume":"18","author":"S Giacchetti","year":"2000","unstructured":"Giacchetti S, Perpoint B, Zidani R et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1):136\u2013147","journal-title":"J Clin Oncol"},{"issue":"12","key":"3037_CR40","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/jnci\/82.12.1046","volume":"82","author":"JP Caussanel","year":"1990","unstructured":"Caussanel JP, L\u00e9vi F, Brienza S et al (1990) Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 82(12):1046\u20131050","journal-title":"J Natl Cancer Inst"},{"issue":"15","key":"3037_CR41","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.ejca.2005.06.021","volume":"41","author":"F Maindrault-Goebel","year":"2005","unstructured":"Maindrault-Goebel F, Andr\u00e9 T, Tournigand C et al (2005) Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 41(15):2262\u20132267","journal-title":"Eur J Cancer"},{"issue":"4","key":"3037_CR42","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000205263","volume":"76","author":"BH Kim","year":"2009","unstructured":"Kim BH, Bradley T, Tai J (2009) Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology Williston Park 76(4):231\u2013238","journal-title":"Oncology Williston Park"},{"issue":"1\u20132","key":"3037_CR43","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000320613","volume":"79","author":"Y Mori","year":"2010","unstructured":"Mori Y, Nishimura T, Kitano T et al (2010) Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. Oncology 79(1\u20132):136\u201343","journal-title":"Oncology"},{"issue":"5","key":"3037_CR44","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3727\/096504017X15139039328978","volume":"26","author":"Y Shen","year":"2018","unstructured":"Shen Y, Li C, Liu W et al (2018) Clinical analysis of hypersensitivity reactions to oxaliplatin among colorectal cancer patients. Oncol Res 26(5):801\u2013807","journal-title":"Oncol Res"},{"issue":"3","key":"3037_CR45","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","volume":"24","author":"C Tournigand","year":"2006","unstructured":"Tournigand C, Cervantes A, Figer A et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer\u2014a GERCOR study. J Clin Oncol 24(3):394\u2013400","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03037-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03037-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03037-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T18:02:28Z","timestamp":1782410548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03037-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3037"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03037-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7362787\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethics review board of the Cancer Institute Hospital of the Japanese Foundation of Cancer Research (registry number 2024-GB-073) and was conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study protocol is described on the hospital\u2019s website, and participants are provided with the option to opt-out. No additional informed consent was obtained from any of the enrolled patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and publish"}}]}}